- Previous Close
33.99 - Open
29.00 - Bid 31.90 x --
- Ask 33.98 x --
- Day's Range
29.00 - 33.99 - 52 Week Range
27.25 - 47.19 - Volume
124 - Avg. Volume
1,884 - Market Cap (intraday)
169.817M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
22.81 - EPS (TTM)
1.49 - Earnings Date May 27, 2025 - May 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Emmessar Biotech & Nutrition Limited, a healthcare company, provides nutritional products in India and internationally. The company operates through Healthcare and Rent on Lease Land segments. It also offers CalmCream, a multi-functional skin cream; Calm Cream RESQ, a skin cream used for burns from sun, radiation, heat and chemicals; Cute-N-Comely, a cosmetic skin cream; MagiCream, a cream used for post-surgical scars; and Muscle Flex Gel, a gel used to relieve pain from aching muscles. In addition, the company offers vedaceuticals, a ayurveda disease curing medicine. Further, it provides healthcare products for dermatology, osteoporosis, anti-ageing, and other healthcare needs. The company was formerly known as Emmessar Chemical Industries Ltd. and changed its name to Emmessar Biotech & Nutrition Limited in April 2000. Emmessar Biotech & Nutrition Limited was incorporated in 1992 and is based in Mumbai, India.
www.ebnl.org17
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: EMMESSA.BO
View MorePerformance Overview: EMMESSA.BO
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EMMESSA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EMMESSA.BO
View MoreValuation Measures
Market Cap
169.82M
Enterprise Value
100.93M
Trailing P/E
22.81
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.69
Price/Book (mrq)
2.19
Enterprise Value/Revenue
17.10
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
38.24%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
19.7M
Net Income Avi to Common (ttm)
7.53M
Diluted EPS (ttm)
1.49
Balance Sheet and Cash Flow
Total Cash (mrq)
66.54M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--